PARP9

Protein mono-ADP-ribosyltransferase PARP9 · Q8IXQ6 · PARP9 on Sugi Atlas →

495 patent compounds predicted against PARP9, 298 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Rucaparib (SCHEMBL844585)	1.00	1/20
Rucaparib (SCHEMBL29351768)	1.00	1/20
Rucaparib (SCHEMBL5746065)	0.98	1/20
Rucaparib (SCHEMBL29392034)	0.98	1/20
Rucaparib (SCHEMBL844872)	0.90	1/20
Rucaparib (SCHEMBL5747917)	0.90	1/20
Rucaparib (SCHEMBL6701932)	0.90	1/20
Rucaparib (SCHEMBL29379028)	0.90	1/20
Rucaparib (SCHEMBL30413070)	0.87	1/20
Rucaparib (SCHEMBL6702365)	0.84	1/20
SCHEMBL25150522	0.81	1/20
SCHEMBL5001964	0.80	1/20
SCHEMBL24302090	0.80	1/20
SCHEMBL27293629	0.79	1/20
SCHEMBL22339866	0.78	1/20
SCHEMBL25149880	0.78	1/20
SCHEMBL30364429	0.78	1/20
SCHEMBL20353975	0.78	1/20
SCHEMBL20349320	0.77	1/20
SCHEMBL25150536	0.77	1/20

Clinical trials — most relevant to PARP9 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients	PHASE3	COMPLETED
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib	PHASE2	COMPLETED
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
Olaparib In Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma	PHASE2	COMPLETED
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)	PHASE2	RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations	PHASE2	COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
Pre-Operative Radiation and Veliparib for Breast Cancer	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer	PHASE1	UNKNOWN
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems	PHASE1	WITHDRAWN
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer	PHASE1	COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults	PHASE1	RECRUITING
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer	nan	NO_LONGER_AVAILABLE
Sirtuin1 in COVID19 Patients	nan	UNKNOWN
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PARP9 binder may also engage these)

Protein	Name	Similarity
Q8CAS9	—	0.996	Q8CAS9 →
PARP15	Protein mono-ADP-ribosyltransferase PARP15	0.989	landscape →
PARP14	Protein mono-ADP-ribosyltransferase PARP14	0.981	landscape →
B1ARD8	—	0.980	B1ARD8 →
A0JPF9	—	0.978	A0JPF9 →
Q5RCZ8	—	0.977	Q5RCZ8 →
Q68D06	—	0.977	Q68D06 →
Q7Z7L1	—	0.977	Q7Z7L1 →
Q09YN0	—	0.977	Q09YN0 →
Q9UII4	—	0.977	Q9UII4 →
Q2IBF5	—	0.977	Q2IBF5 →
Q6ZSC3	—	0.976	Q6ZSC3 →
SLFN12	Ribonuclease SLFN12	0.976	landscape →
Q8VD46	—	0.976	Q8VD46 →
Q5DJU3	—	0.976	Q5DJU3 →
Q14CZ7	—	0.976	Q14CZ7 →
Q2EMV9	—	0.976	Q2EMV9 →
Q8C0W1	—	0.976	Q8C0W1 →
Q8NE18	—	0.975	Q8NE18 →
Q2IBB1	—	0.975	Q2IBB1 →
Q2QLA4	—	0.975	Q2QLA4 →
Q008S8	—	0.975	Q008S8 →
Q07DY6	—	0.975	Q07DY6 →
Q5K651	—	0.974	Q5K651 →
Q07DZ7	—	0.974	Q07DZ7 →
B1ARD6	—	0.974	B1ARD6 →
Q502W6	—	0.974	Q502W6 →
Q2TB18	—	0.974	Q2TB18 →
Q8C8H8	—	0.974	Q8C8H8 →
Q5U311	—	0.974	Q5U311 →